EPI-743 is an orally bioavailable small molecule in thepara-benzoquinone drug class, and is currently under development by Edison forinherited mitochondrial diseases. EPI-589 is a next-generation, reversibleredox cofactor being developed to treat a variety of adult diseases. EPI-743 iscurrently in Phase II clinical development for the treatment of inheritedrespiratory chain disorders, with double-blind, placebo-controlled trialsunderway for the following indications: Leigh syndrome, Friedreich's ataxia,Cobalamin C defect and undiagnosed disorders of oxidation-reduction. Theproceeds from this partnership will be used to advance the late-stagedevelopment and commercialization of the compound for Leigh syndrome andFriedreich's ataxia, and for the advancement of EPI-743 in other exploratory PhaseII trials in the field of mitochondrial diseases.
Edison's translational technology platform is based on redoxbiochemistry. Redox chemistry is the basis of how cells make and regulateenergy metabolism, "the physical chemistry and biochemistry of reversibleelectron transfer reactions," Edison notes on its website. Edison translatesdiscoveries related to genetically confirmed, rare pediatric mitochondrialdiseases to adult central nervous system disorders, in which redox andmitochondrial dysfunction are also significant issues.
SOURCE: Edison press release
